Physician profile
Lisa E Jefferson
NPI 1578502969
$474.08
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $26.10 · 2022: $15.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $154.76 | 2019 | |
| Pfizer INC. | $37.32 | 2019 | |
| Abbvie INC. | $27.18 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $26.37 | 2019-2020 | |
| Genentech USA, INC. | $24.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.69 | 2019 | |
| Astellas Pharma US INC | $20.23 | 2019 | |
| Dermira, INC. | $19.97 | 2019 | |
| Sanofi Pasteur INC. | $18.08 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.71 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.77 | 2019 | |
| Gilead Sciences, INC. | $14.43 | 2019 | |
| Lilly USA, LLC | $14.06 | 2019 | |
| Hikma Pharmaceuticals USA | $13.36 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.03 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12.69 | 2019 | |
| Allergan, INC. | $11.97 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Jefferson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.